Battling DR-TB in Khayelitsha
‘If you look for it (drug-resistant TB), you will find it,’ said Dr Helen Cox of Médecins Sans Frontières (MSF).
In Africa, there is a low percentage of drug-resistant TB reported among new cases compared with regions such as Eastern Europe and Central Asia. However, there is an understanding that this may be due in part to the limited laboratory capacity to conduct drug resistance surveys.
Current data reveals 28% of all people newly diagnosed with TB in one region of north western Russia had the multidrug-resistant form of the disease in 2008. This is the highest level ever reported to the World Health Organisation. Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in 2007.
Cox and her colleagues (including the city and provincial health services) conducted a survey in Khayelitsha in 2008 among TB patients and found that 5% of the new TB patients (223) were resistant to rifampicin, the most effective anti-TB drug.
Rifampicin resistance was also found in 168 (11%) of the previously treated cases. This translated into 391 patients with rifampicin resistance which is 80 patients per 100 000 cases, higher than in most East European countries. In 2009, 17% of the Khayelitsha patients found were resistant to one or more of the TB drugs.
Cox said that many patients also died before they were diagnosed or able to access treatment. In Khayelitsha it was found that as many as 10% of patients died before they received the results confirming whether they had drug-resistant TB. The drug sensitivity tests take between eight and 10 weeks.
She said early detection of drug-resistant TB was critical and that new diagnostics had to be fast tracked. The Gene Xpert cuts the diagnosis to 90 minutes and is simple to operate, but it is unaffordable for most high burden countries.
Despite this grim picture MSF was recording massive improvements in outcomes by diagnosing patients, educating them regarding their treatment, giving support at home, treating them as outpatients and implementing infection control in the home and at the clinics.
After 18 months 60% of drug-resistant patients on the MSF programme were still alive, compared to 70% of patients dying in similar settings around the world.
Cox said the new anti-TB drug Moxifloxacin was showing great promise in Khayelitsha, but that is was very expensive. ‘We need advocacy to push for it to become more affordable,’ she said.
· Multidrug-resistant TB (MDR-TB) is caused by bacteria that are resistant to at least isoniazid and rifampicin, the most effective anti-TB drugs. MDR-TB results from either primary infection with resistant bacteria or may develop in the course of a patient’s treatment.
· Extensively drug-resistant TB (XDR-TB) is a form of TB caused by bacteria that are resistant to isoniazid and rifampicin (i.e. MDR-TB) as well as any fluoroquinolone and any of the second-line anti-TB injectable drugs (amikacin, kanamycin or capreomycin). These forms of TB do not respond to the standard six-month treatment with first-line anti-TB drugs and can take up to two years or more to treat with drugs that are less potent, more toxic and much more expensive, from 50 to 200 times higher. While a course of standard TB drugs cost approximately US$ 20, MDR-TB drugs can cost up to US$ 5 000, and XDR-TB treatment is far more expensive.
Author
Health-e News is South Africa's dedicated health news service and home to OurHealth citizen journalism. Follow us on Twitter @HealtheNews
View all posts
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
Battling DR-TB in Khayelitsha
by Health-e News, Health-e News
November 13, 2010